 |
市场调查报告书
商品编码
1741151
细菌疫苗市场按疫苗类型、患者年龄层、给药途径、销售管道和地区划分Bacterial Vaccines Market, By Vaccine Type, By Patient Age Group, By Route of Administration, By Distribution Channel, By Geography |
||||||
价格
简介目录
细菌疫苗市场规模预计在 2025 年为 277.2 亿美元，预计到 2032 年将达到 475.1 亿美元，2025 年至 2032 年的复合年增长率为 8%。
| 报告范围 | 报告详细信息 | ||
|---|---|---|---|
| 基准年 | 2024 | 2025年的市场规模 | 277.2亿美元 |
| 效能数据 | 从2020年到2024年 | 预测期 | 2025年至2032年 |
| 预测期：2025-2032年复合年增长率： | 8.00% | 2032年价值预测 | 475.1亿美元 |
细菌疫苗含有能够活化免疫系统的弱化或灭活细菌。它是预防医学中对抗结核病、霍乱、炭疽、流感、破伤风、脑膜炎、伤寒等感染疾病的重要方法。政府和非政府组织正在进行多项项目，以宣传包括感染疾病在内的预防医学的益处。
市场动态：
预计全球细菌疫苗市场在预测期内将显着成长。这主要是因为世界各国政府正在采取重大倡议，确保全球人口能够获得预防致命感染疾病的药物。此外，疫情期间疫苗接种需求的增加也推动了市场的发展。此外，新型感染疾病去氧核糖核酸(DNA) 疫苗的推出也推动了市场的发展。 COVID-19 疫情影响了各种 DNA 疫苗的研发，从而对细菌疫苗市场的成长产生了积极影响。抗生素抗药性细菌性疾病发生率的上升再次推动了细菌疫苗市场的成长。这促使主要市场参与者专注于开发更有效的感染疾病并投资于研究活动。
然而，对细菌性疾病缺乏认识预计会阻碍细菌疫苗市场的成长。
例如，2023年9月28日，英国政府决定向伯明罕大学主办的细菌疫苗网络（BactiVac）提供140万美元的资助，以加速开发细菌疫苗，预防感染疾病爆发，这是全球抗抗抗生素抗药性（AMR）行动的一部分。细菌疫苗在对抗AMR方面发挥关键作用，可以预防感染疾病的发生并减少抗生素的使用需求。
本研究的主要特点
- 本报告对全球细菌疫苗市场进行了详细分析，并以 2024 年为基准年，提供了 2025 年至 2032 年预测期内的市场规模和年复合成长率(CAGR)。
- 它还强调了各个领域的潜在商机，并说明了该市场的有吸引力的投资提案矩阵。
- 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
- 它根据公司亮点、产品系列、关键亮点、财务表现和策略等参数，介绍了全球细菌疫苗市场的主要企业概况。
- 本报告的见解将使负责人和企业经营团队能够就未来的产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
- 全球细菌疫苗市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
- 相关人员将透过用于分析全球细菌疫苗市场的各种策略矩阵来做出决策。
目录
第一章 调查目的与前提条件
- 研究目标
- 先决条件
- 简称
第二章 市场展望
- 报告描述
- 市场定义和范围
- 执行摘要
- Coherent Opportunity Map（COM）
第三章市场动态、法规与趋势分析
- 市场动态
- 司机
- 限制因素
- 机会
- 主要亮点
- 监管情景
- 近期动态
- 产品发布/核准
- PEST分析
- 波特分析
- 合併、收购和合作
4. 全球细菌疫苗市场-冠状病毒（COVID-19）大流行的影响
- COVID-19流行病学
- 供需侧分析
- 经济影响
5. 2020 年至 2032 年全球细菌疫苗市场（依疫苗类型）
- 百日咳疫苗
- 破伤风疫苗
- 白喉疫苗
- 肺炎链球菌疫苗
- 脑膜炎双球菌疫苗
- 伤寒疫苗
- 结核病（TB）疫苗
- 霍乱疫苗
- 志贺氏菌病疫苗
- 其他的
6. 2020-2032 年全球细菌疫苗市场（依病患年龄层）
- 儿童疫苗（婴儿、儿童）
- 青少年疫苗
- 成人疫苗
- 老年人疫苗
7. 2020 年至 2032 年按给药途径分類的全球细菌疫苗市场
- 肌肉注射
- 静脉
- 皮下
- 其他的
8. 2020 年至 2032 年全球细菌疫苗市场（依通路）
- 公共
- 私人的
9. 2020 年至 2032 年全球细菌疫苗市场（按地区）
- 北美洲
- 美国
- 加拿大
- 欧洲
- 德国
- 英国
- 西班牙
- 法国
- 义大利
- 俄罗斯
- 其他欧洲国家
- 亚太地区
- 中国
- 印度
- 日本
- 澳洲
- 韩国
- ASEAN
- 其他亚太地区
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
- 中东
- 海湾合作委员会国家
- 以色列
- 其他中东地区
- 非洲
- 南非
- 北非
- 中部非洲
第十章 竞争格局
- Company Profie
- GSK plc
- Pfizer Inc.
- Merck & Co., Inc.
- Sanofi
- Johnson & Johnson Service, Inc.
- Serum Institute of India Pvt. Ltd.
- Bharat Biotech
- Biological E. Limited
- Astellas Pharma Inc.
- Seqirus（CSL Limited）
- AstraZeneca
- Novavax, Inc.
- Bavarian Nordic A/S
- Emergent BioSolutions Inc.
- Valneva SE
- Takeda Pharmaceutical Company Limited
- Boehringer Ingelheim International GmbH
- Immunomic Therapeutics, Inc.
- Moderna, Inc.
- Clover Biopharmaceuticals
- Analysts'Views
第 11 章 章节
- 参考
- 调查方法
- 关于出版商
简介目录
Product Code: CMI5877
Bacterial Vaccines Market is estimated to be valued at USD 27.72 Bn in 2025 and is expected to reach USD 47.51 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 27.72 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 8.00% | 2032 Value Projection: | USD 47.51 Bn |
Bacterial vaccines contain mild or killed forms of bacteria that activate the immune system. This is a vital method for preventive medicine to fight infections like tuberculosis, cholera, anthrax, influenza, tetanus, meningitis, and typhoid. Several programs are carried out by governments and non-governmental organizations to spread awareness about the benefits of the preventive medicines including vaccines against infectious diseases.
Market Dynamics:
Global bacterial vaccines market is expected to grow at a substantial rate during the forecast period. This is mainly due to significant initiatives undertaken by governments across the globe to ensure that the preventive medicine for lethal infectious diseases is available for the population across the world. The market is also fueled by the increasing demand for vaccinations during pandemics. Moreover, the market is driven by the launch of new Deoxyribonucleic acid (DNA) vaccines against infectious diseases. The Covid-19 pandemic has influenced the development of a variety of DNA vaccines and hence positively impacted the growth of the bacterial vaccines market. The rising incidence of antibiotic-resistant bacterial diseases is again driving the growth of bacterial vaccines market. This is influencing the key market players to invest in research activities by focusing on developing more effective vaccines against infectious diseases.
However, lack of awareness regarding the bacterial disease is expected to hinder the market growth of the bacterial vaccines
For instance, on September 28, 2023, the U.K. government awarded the University of Birmingham-hosted Bacterial Vaccines Network (BactiVac) US$ 1.4 million in funding to accelerate the development of bacterial vaccines in a bid to prevent infections from occurring as part of the global fight against antimicrobial resistance (AMR). Bacterial vaccines play a critical role in the fight against AMR, both through preventing infections from developing and reducing the need to use antimicrobials.
Key features of the study:
- This report provides in-depth analysis of the global bacterial vaccines market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global bacterial vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include GSK plc., Pfizer Inc., Merck & Co., Inc., Sanofi, Johnson & Johnson Service, Inc., Serum Institute of India Pvt. Ltd., Bharat Biotech Biological E. Limited, Astellas Pharma Inc., Seqirus (CSL Limited), AstraZeneca, Novavax, Inc., Bavarian Nordic A/S, Emergent BioSolutions Inc., Valneva SE, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Immunomic Therapeutics, Inc., Moderna, Inc., Clover Biopharmaceuticals
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global bacterial vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bacterial vaccines market
Global Bacterial Vaccines Market Detailed Segmentation:
- By Vaccine Type
- Pertussis (Whooping Cough) Vaccines
- Tetanus Vaccines
- Diphtheria Vaccines
- Pneumococcal Vaccines
- Meningococcal Vaccines
- Typhoid Vaccines
- Tuberculosis (TB) Vaccines
- Cholera Vaccines
- Shigellosis Vaccines
- Others
- By Patient Age Group
- Pediatric Vaccines (Infants, Children)
- Adolescent Vaccines
- Adult Vaccines
- Geriatric Vaccines
- By Route of Administration
- Intramuscular
- Intravenous
- Subcutaneous
- Others (Oral, Nasal among others)
- By Distribution Channel
- Public
- Private
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
- Company Profile
- GSK Plc
- Pfizer Inc.
- Merck & Co., Inc.
- Sanofi
- Johnson & Johnson Service, Inc.
- Serum Institute of India Pvt. Ltd.
- Bharat Biotech
- Biological E. Limited
- Astellas Pharma Inc.
- Seqirus (CSL Limited)
- AstraZeneca
- Novavax, Inc.
- Bavarian Nordic A/S
- Emergent BioSolutions Inc.
- Valneva SE
- Takeda Pharmaceutical Company Limited
- Boehringer Ingelheim International GmbH
- Immunomic Therapeutics, Inc.
- Moderna, Inc.
- Clover Biopharmaceuticals
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Vaccine Type
- Market Snippet, By Patient Age Group
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraints
- Opportunities
- Key Highlights
- Regulatory Scenario
- Recent Trends
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Mergers, Acquisitions, and Collaborations
4. Global Bacterial Vaccines Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Bacterial Vaccines Market, By Vaccine Type, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pertussis (Whooping Cough) Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Tetanus Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Diphtheria Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Pneumococcal Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Meningococcal Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Typhoid Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Tuberculosis (TB) Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Cholera Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Shigellosis Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
6. Global Bacterial Vaccines Market, By Patient Age Group, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pediatric Vaccines (Infants, Children)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Adolescent Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Adult Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Geriatric Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
7. Global Bacterial Vaccines Market, By Route of Administration, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Intramuscular
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
8. Global Bacterial Vaccines Market, By Distribution Channel, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Public
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Private
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
9. Global Bacterial Vaccines Market, By Region, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021 -2032
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age Group, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age Group, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age Group, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age Group, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age Group, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age Group, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032,(US$ Bn)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- Company Profie
- GSK plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Johnson & Johnson Service, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Serum Institute of India Pvt. Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bharat Biotech
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Biological E. Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Seqirus (CSL Limited)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novavax, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bavarian Nordic A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Emergent BioSolutions Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Valneva SE
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Boehringer Ingelheim International GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Immunomic Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Moderna, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Clover Biopharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analysts' Views
11. Section
- References
- Research Methodology
- About us
